Tissue Proteomic Signatures of BRAF -Mutated Colorectal Cancer Reveal New Insights into Aggressiveness, Immune Modulation, and Metabolic Reprogramming
Journal of Proteome Research · 2026
DOI: 10.1021/acs.jproteome.6c00178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, 2026. Verfasst von Gianmaria Miolo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology and Cancer Prevention Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081Aviano (PN), Italy. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Proteomics, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Italian Ministry of Health-Ricerca Corrente, Italy.
Abstract (Originalsprache)
Colorectal cancer (CRC) is characterized by molecular heterogeneity, with BRAF-mutated tumors being particularly aggressive and refractory to standard therapies. This study aimed to identify distinctive proteomic signatures associated with the BRAF V600E mutation through comparative tumor tissue profiling. Thirty-three tumor tissues were analyzed: 9 BRAF-mutated, 14 RAS-mutated, and 10 wild-type (WT). Proteomic profiling was performed on formalin-fixed, paraffin-embedded (FFPE) tissues using bottom-up LC–MS/MS in a data-independent acquisition mode. Protein identification and relative expression were achieved by using DIA-NN label-free analysis. Group differences were evaluated through multiparametric analyses, and Cox proportional hazard models were applied to identify proteins associated with overall survival. BRAF-mutated tumors showed distinct proteomic alterations, including overexpression of dipeptidyl peptidase 4 (DPP4) and lysophosphatidylcholine acyltransferase 1 (LPCAT1) alongside the downregulation of quinolinic phosphoribosyltransferase (QPRT) involved in NAD+ biosynthesis. Pathway analysis revealed the enrichment of protein folding associated with endoplasmic reticulum (ER) stress. Prognostic accuracy improved when tumor genotype was combined with the expression of activator of HSP90 ATPase activity 1 (AHSA1) and thioredoxin domain-containing 5 (TXNDC5), involved in ER-associated protein folding. These findings define a distinctive proteomic signature in BRAF-mutated CRC, characterized by dysregulated protein folding associated with ER stress and supporting the development of targeted therapies and more precise prognostic models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology and Cancer Prevention Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081Aviano (PN), Italy.
- Pathology Unit, Department of Medicine Laboratory Section, Pordenone Hospital, Pordenone33170, Italy.
- Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081Aviano (PN), Italy.
- Department of Medicine, University of Udine, 33100Udine, Italy.
ORCID-Profile: Gianmaria Miolo, Giovanni Canil
Förderung
- Italian Ministry of Health-Ricerca Corrente, Italy
Zitieren
APA
Miolo, G., Marus, W., Canil, G., Inversi, A., Puglisi, F., & Corona, G. (2026). Tissue Proteomic Signatures of BRAF -Mutated Colorectal Cancer Reveal New Insights into Aggressiveness, Immune Modulation, and Metabolic Reprogramming. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.6c00178
Vancouver
Miolo G, Marus W, Canil G, Inversi A, Puglisi F, Corona G. Tissue Proteomic Signatures of BRAF -Mutated Colorectal Cancer Reveal New Insights into Aggressiveness, Immune Modulation, and Metabolic Reprogramming. Journal of Proteome Research. 2026. doi:10.1021/acs.jproteome.6c00178
BibTeX
@article{Miolo2026,
author = {Miolo, Gianmaria and Marus, Wally and Canil, Giovanni and Inversi, Amy and Puglisi, Fabio and Corona, Giuseppe},
title = {Tissue Proteomic Signatures of BRAF -Mutated Colorectal Cancer Reveal New Insights into Aggressiveness, Immune Modulation, and Metabolic Reprogramming},
journal = {Journal of Proteome Research},
year = {2026},
doi = {10.1021/acs.jproteome.6c00178}
}
EUVIMED